Intuitive Surgical (ISRG) Earnings Date & Reports
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery... Show more
ISRG is expected to report earnings to $2.51 per share on July 16
Intuitive Surgical (ISRG) Q1 2026 Earnings Recap: Revenue Surges 23% on Procedure Boom
Key Takeaways
- Revenue reached $2.77 billion, up 23% year-over-year and beating consensus estimates of $2.62 billion.+Tops+Q1+EPS+by+38c/26344569.html)
- Non-GAAP EPS came in at $2.50, surpassing expectations of around $2.12; GAAP EPS was $2.28.
- Worldwide procedures grew 17%, with da Vinci procedures up 16% to approximately 847,000 and Ion up 39%.
- Placed 431 da Vinci systems, including 232 da Vinci 5 systems, up from 367 total last year.
- Full-year 2026 guidance calls for da Vinci procedure growth of 13.5% to 15.5%.
- Non-GAAP operating margin expanded to 39%.
Earnings Context and Why It Matters
Intuitive Surgical, a leader in robotic-assisted minimally invasive surgery, reported Q1 2026 results that underscore its dominant position in the da Vinci ecosystem. With procedures representing the bulk of recurring revenue from instruments and accessories (up 23% to $1.69 billion), this quarter highlights sustained demand for its systems amid expanding adoption of advanced platforms like da Vinci 5. Investors watch these metrics closely as they signal long-term growth in surgical robotics, a market projected to benefit from aging populations and shifts toward less invasive procedures. Strong results reinforce ISRG's premium valuation but also spotlight execution risks in global expansion.
Intuitive Surgical delivered a robust Q1 2026, exceeding Wall Street expectations across key lines. Total revenue climbed 23% to $2.77 billion from $2.25 billion a year ago, topping the $2.62 billion consensus. Instruments and accessories, which comprised 61% of revenue, rose 23% to $1.69 billion on higher procedure volumes. Systems revenue jumped to $651 million from $523 million, fueled by 431 placements versus 367 prior year.
GAAP net income attributable to Intuitive Surgical hit $822 million, or $2.28 per diluted share, up from $698 million or $1.92. Non-GAAP EPS of $2.50 beat estimates by about 18%. Operating income (GAAP) expanded to $855 million, with non-GAAP at $1.08 billion. Procedure growth was broad-based: 17% total (da Vinci + Ion), driven by 16% da Vinci and 39% Ion increases. The installed base grew to 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%).
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
ISRG shares showed mixed initial reaction post-earnings, dipping modestly in after-hours trading before recovering with gains of around 0.7% to 3.8% in extended sessions, reflecting digestion of the beat tempered by full-year guidance implying some deceleration from Q1's pace. Sentiment remains positive on procedure momentum and da Vinci 5 traction, though investors noted tariff impacts and conservative outlook as potential headwinds. Trading volume spiked, underscoring high interest in robotics growth prospects.+Releases+Q1+2026+Earnings,+Stock+Rises)
Forward Outlook and Key Factors to Monitor
Intuitive Surgical raised its full-year 2026 guidance for da Vinci procedure growth to 13.5%-15.5%, signaling confidence despite a step-down from Q1's 17% total growth. This reflects broad adoption but accounts for potential seasonal patterns and external pressures like tariffs, estimated at 1% of revenue impact on gross margins (guided 67.5%-68.5%). Non-GAAP operating expenses are expected to rise 11%-14%.
Investors should track da Vinci 5 placements, which hit 232 units this quarter (up from 147), as higher average selling prices and utilization drive recurring revenue. Ion platform expansion (39% procedure growth) offers diversification beyond general surgery. Global procedure trends, particularly in emerging markets, and customer buying patterns will be critical. Regulatory updates, supply chain stability amid tariffs, and share repurchases ($1.1 billion in Q1) also merit attention as the company ends the quarter with $7.98 billion in cash.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther